Gadobenate, Gadodiamide & Gadopentetate Integral Tools for Contrast Media


Brain MRIThe demand for MRIs is substantial worldwide, with the greatest need being for brain, head and neck scans. Spinal and extremity scans are a close second in terms of most requested MRI procedures in the United States. The unique ability of an MRI scan to effectively use both radio waves and large magnets to view bodily structures and organs makes this tool a pivotal development in modern medicine. Practitioners value the precision of the MRI for diagnosing a wide variety of health conditions, ranging from torn ligaments to growing tumors. The use of contrast media agents, like Gadobenate, Gadodiamide and Gadopentetate are integral for proper diagnostics and effectual patient treatment. With the global MRI market valued at roughly seven billion dollars this medical technology is only going to be seeing an increasing demand.

The use of Gadolinium-based contrast agents, also known as GBCAs, are available for patients who need a contrast imaging drug to achieve an accurate diagnosis. Patients with kidney disease are at risk for acute kidney injury if they are administered a GBCA. However, the majority of patients have no adverse effects from contrast media injector GBCAs. Several types of contrast media injectors are available:

  • Gadobenate DimeglumineGadobenate Dimeglumine– known as the brand name MultiHance, this sterile injectable contains 529 milligrams of Gadobenate Dimeglumine per mL, mixed with water. This agent is efficacious and tolerable for patient ages two and older for viewing the central nervous system via an MRI. Gadobenate Dimeglumine is often used in an MRI to view abnormal vascularity of the brain or spine, as well as for seeing lesions which have abnormal blood barriers. Clinical trials of Gadobenate Dimeglumine involving almost 3000 patients showed side effects to be mild headache and/or nausea for roughly 1 percent of the patient population. As a paramagnetic agent Gadobenate Dimeglumine enhances the magnetic relaxation rates of water protons, thus leading to increased signal intensity and brightness in tissue appearance.
  • GadodiamideGadodiamide– also known as the brand name Omniscan, this formulation of the gadolinium complex consisting of diethylenetriamine pentaacetic acid bismethylamide is a targeted, nonionic enhancing agent. Like Gadobenate Dimeglumine, Gadodiamide is administered via an intravenous injection and has proven to be both safe and tolerable in the vast majority of patients. Clinical studies of 1,160 patients revealed that slightly less than 3 percent of people who received Gadodiamide as Omniscan experienced mild to moderate adverse effects of nausea, headache and dizziness. Gadodiamide is used for visualizing intracranial and spinal lesions.
  • gadopentetateGadopentetate– Magnevist is the brand name for this GBCA. Each injection of this agent contains 469.01 milligrams of Gadopentetate Dimeglumine, 0.99 milligrams of meglumine, 0.40 milligrams of diethylenetriamine pentaacetic acid and water. Gadopentetate is used not only for examining brain abnormalities, it is also regularly relied upon for the visualization of lesions with abnormal vascularity throughout the body in adults and children over the age of two. Clinical trials of 1, 272 patients showed few adverse effects were reported by patients. A minor 4.8 percent of patients that received Gadopentetate reported a slight headache after administration.

Every year approximately 10 million patients undergo MRI procedures, with little or no negative effects. The use of GBCAs in the MRI procedure have proven to elicit no pain or tissue damage to the patient. LGM Pharma can assist clients as a supplier/distributor of the APIs Gadobenate Dimeglumine, CAS# 127000-20-8, Gadodiamide, CAS# 122795-43-1 and Gadopentetate, CAS# 20694-16-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: